Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04784533 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
A Phase 2 study, sponsored by Concert Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 317
- Enrollment target
NCT04784533 is a Phase 2 study that has completed, run by Concert Pharmaceuticals. The registered enrollment target is 317 participants.
The verdict
NCT04784533, a Phase 2 study, has completed, sponsored by Concert Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 317 participants
- Enrollment target
Study Summary
This study is designed to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.
Interventions
- DRUG Placebo
- DRUG CTP-543
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2021-02-26 |
| Est. Completion | 2023-05-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04784533
The ClinicalTrials.gov registry entry for NCT04784533 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Concert Pharmaceuticals, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04784533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04784533 about?
NCT04784533 is a clinical study titled "A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata". This study is designed to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.
What is the current status of trial NCT04784533?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 317 participants. The study started on 2021-02-26. Estimated completion is 2023-05-16.
What interventions are being tested in trial NCT04784533?
The interventions under investigation include: Placebo (DRUG), CTP-543 (DRUG).
Who is sponsoring clinical trial NCT04784533?
This trial is sponsored by Concert Pharmaceuticals, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.